efficaci
antitumor
vaccin
depend
larg
extent
antigen
target
dendrit
cell
dc
assess
antitumor
immun
induc
attenu
coronaviru
vector
exclus
target
dc
vivo
express
either
lymphocyteor
dcactiv
cytokin
combin
gfptag
model
antigen
track
vivo
transduc
dc
reveal
vector
encod
fmslike
tyrosin
kinas
ligand
exhibit
higher
capac
induc
dc
matur
compar
vector
deliv
moreov
vector
effici
induc
tumorspecif
cell
expand
epitop
repertoir
provid
prophylact
therapeut
tumor
immun
contrast
vector
show
substanti
lower
efficaci
cell
prime
fail
protect
host
tumor
establish
thu
specif
vivo
target
dc
coronaviru
vector
conjunct
appropri
condit
microenviron
repres
effici
strategi
gener
therapeut
antitumor
immun
immunotherapi
cancer
move
preclin
develop
clinic
practic
exampl
prophylact
vaccin
use
nonself
antigen
virusderiv
protein
human
papilloma
virus
reduc
incid
virusinduc
tumor
moreov
descript
tumorassoci
self
antigen
open
new
avenu
vaccin
approach
target
erad
establish
tumor
cell
inde
recent
phase
iii
trial
shown
patientspecif
cellular
vaccin
contain
tumor
antigen
improv
surviv
patient
even
advanc
diseas
howev
sinc
product
tailor
vaccin
individu
patient
requir
labori
expens
routin
gener
simpl
effici
offtheshelf
reagent
foster
biolog
factor
make
develop
therapeut
antitumor
vaccin
cumbersom
includ
immunosuppress
microenviron
within
tumor
tissu
remot
inhibitori
effect
preferenti
differenti
regulatori
treg
cell
propos
combin
tumor
antigen
immunemodulatori
cytokin
overcom
tumorinduc
immunosuppress
andor
deviat
cytokin
foster
activ
lymphocyt
evalu
preclin
model
current
test
clinic
studi
augment
tumorspecif
immun
likewis
cytokin
act
mainli
myeloid
cell
granulocyt
macrophag
colonystimul
factor
gmcsf
fmslike
tyrosin
kinas
ligand
shown
improv
efficaci
cancer
vaccin
howev
cytokin
gener
exhibit
wide
rang
function
exampl
potent
stimulu
activ
cell
foster
time
activationinduc
cell
death
effector
cell
induc
treg
cell
tumor
patient
likewis
gmcsf
foster
gener
surviv
myeloid
suppressor
cell
henc
import
cancer
vaccin
deliv
pleiotrop
cytokin
cell
optim
induc
maintain
anticanc
immun
respons
dendrit
cell
dc
sampl
antigen
peripher
organ
transport
immunogen
materi
secondari
lymphoid
organ
initi
maintain
b
cell
respons
dc
appropri
stimul
achiev
full
differenti
cell
overcom
potenti
toler
stimuli
within
microenviron
secondari
lymphoid
organ
notabl
import
dc
directli
activ
patternrecognit
receptor
achiev
full
matur
success
induc
reject
tumor
attenu
viral
vector
exhibit
sever
import
advantag
make
attract
vaccin
vehicl
antitumor
vaccin
first
viral
vaccin
produc
larg
quantiti
store
offtheshelf
reagent
second
virus
gener
infect
profession
antigen
present
cell
dc
third
viral
infect
trigger
dc
matur
recent
suggest
util
attenu
coronavirus
vaccin
vector
positivestrand
rna
virus
replic
exclus
cytoplasm
without
dna
intermediari
ii
recent
technolog
advanc
permit
heavi
attenu
without
loss
immunogen
iii
larg
rna
genom
offer
larg
clone
capac
iv
human
murin
coronavirus
effici
target
dc
previou
studi
found
murin
coronavirusbas
vector
deliv
multipl
antigen
cytokin
almost
exclus
dc
within
secondari
lymphoid
organ
moreov
induct
cell
direct
human
tumor
antigen
effici
transduct
human
dc
tumor
antigenrecombin
human
coronaviru
indic
coronavirusmedi
gene
transfer
dc
consid
versatil
approach
antitumor
vaccin
present
studi
evalu
impact
lymphoid
cytokin
coexpress
gfptag
model
antigen
murin
coronaviru
vector
antitumor
immun
found
dc
transduc
vivo
vector
encod
effici
activ
tumorspecif
cell
broaden
epitop
repertoir
secur
therapeut
tumor
immun
interestingli
show
significantli
lower
adjuv
effect
cell
prime
fail
protect
establish
tumor
indic
coronavirusmedi
vivo
target
dc
conjunct
myeloid
cellstimul
cytokin
wellsuit
gener
therapeut
antitumor
immun
coronavirusbas
multigen
vaccin
vector
design
basi
mous
hepat
viru
mhv
genom
figur
achiev
propag
defici
maintain
time
replic
compet
mhvencod
accessori
gene
delet
nonstructur
protein
truncat
introduc
mutat
reduc
mhv
pathogen
retain
immunogen
moreov
structur
gene
e
delet
hinder
virion
format
surrog
tumor
antigen
use
fusion
protein
enhanc
green
fluoresc
protein
egfp
cell
epitop
deriv
lymphocyt
choriomening
viru
lcmv
glycoprotein
compar
adjuv
effect
cytokin
act
mainli
myeloid
cell
versu
lymphocyt
gene
encod
murin
insert
replicas
spike
gene
figur
propag
mhvbase
vector
achiev
packag
cell
provid
e
protein
tran
figur
importantli
vector
fail
propag
primari
macrophag
figur
dc
shown
vitro
effici
deliv
antigen
dc
result
transduct
rate
figur
vitro
transduc
periton
macrophag
dc
rapidli
produc
follow
transduct
respect
vector
figur
wherea
could
detect
follow
transduct
shown
notabl
known
cytokin
transpres
henc
usual
measur
use
convent
detect
system
furthermor
found
neither
transduct
mhvgp
vector
induc
three
cytokin
cytokineexpress
vector
elicit
nonspecif
cytokin
product
shown
thu
coronaviru
vector
specif
deliv
antigen
differ
immunemodulatori
cytokin
major
target
cell
shown
previous
murin
coronaviru
preferenti
infect
macrophag
dc
vivo
moreov
sever
attenu
mhv
focuss
target
cell
rang
dc
pronounc
dcspecif
alter
insert
lymphoid
cytokin
follow
iv
applic
vector
particl
mice
egfp
express
detect
mainli
mhcii
ia
b
high
dc
figur
wherebi
cytokin
roughli
doubl
vivo
transduct
efficaci
figur
vivo
deliveri
figur
figur
result
high
cytokin
product
h
wherea
could
neither
detect
serum
spleen
shown
importantli
compar
transient
elev
gmcsf
level
follow
coronavirusmedi
deliveri
level
normal
day
post
applic
shown
sinc
matur
dc
critic
induct
protect
immun
determin
express
matur
marker
vivo
transduc
egfp
dc
shown
figur
vector
led
upregul
matur
marker
interestingli
enhanc
express
restrict
dc
express
egfp
figur
indic
presenc
viral
vector
within
dc
direct
product
myeloid
cellstimul
cytokin
led
optim
dc
matur
compar
adjuv
effect
differ
cytokin
encod
coronaviru
vector
first
assess
magnitud
durat
transgenespecif
cell
activ
addit
determin
cytokinemedi
chang
epitop
usag
monitor
cell
respons
b
bind
b
bind
epitop
present
transgen
use
iv
applic
pfu
vector
found
induct
cell
respons
best
support
lead
superior
expans
tetramerbind
cell
differenti
toward
effector
cell
figur
importantli
initi
expans
cell
follow
vaccin
compar
respons
induc
fulli
replicationcompet
lcmv
figur
surprisingli
although
describ
cytokin
support
gener
memori
cell
vector
better
support
persist
transgenespecif
cell
figur
shown
previous
mhvgp
vector
fail
rais
substanti
respons
b
bind
epitop
figur
likewis
vector
encod
elicit
pronounc
cell
respons
epitop
wherea
vectorencod
promot
broaden
antigen
reactiv
toward
figur
find
corrobor
use
adopt
transfer
tcr
transgen
cell
one
day
applic
vector
effici
support
expans
cell
figur
indic
cytokin
function
optim
adjuv
dcspecif
target
approach
induct
potent
cell
respons
tumor
antigen
critic
establish
maintain
tumor
immun
assess
impact
lymphoid
versu
adjuv
effect
protect
tumor
immun
util
two
differ
tumor
model
provid
compat
lcmvgp
system
due
express
minigen
first
model
assess
metastat
growth
murin
melanoma
cell
end
parent
cell
appli
mice
result
metastat
growth
tumor
cell
lung
figur
vaccin
recipi
mice
day
tumor
challeng
pfu
differ
coronaviru
vector
complet
block
growth
tumor
cell
wherea
format
metastat
foci
lung
parent
cell
affect
figur
moreov
prophylact
vaccin
pfu
encod
vector
reduc
tumor
burden
wherea
dose
vector
complet
prevent
tumor
growth
figur
care
titrat
cytokineencod
vector
dose
compil
sever
seri
experi
prophylact
vaccin
set
reveal
inde
viral
particl
mhvgp
suffici
complet
protect
mice
tumor
challeng
figur
assess
whether
cytokineencod
vector
elicit
therapeut
tumor
immun
mice
first
inocul
tumor
vaccin
day
later
pfu
differ
coronaviru
vector
ten
day
later
ie
day
post
tumor
inocul
melanoma
cell
almost
complet
cover
whole
lung
surfac
control
mhvgp
vaccin
mice
wherea
therapeut
vaccin
cytokineencod
vector
reduc
tumor
load
figur
importantli
determin
affect
lung
surfac
reveal
vaccin
vector
abl
significantli
reduc
tumor
load
figur
clearanc
rapidli
grow
metastat
tumor
certainli
challeng
immun
system
howev
metastat
tumor
melanoma
cell
reach
secondari
lymphoid
organ
therebi
contribut
like
due
mhc
class
express
amplif
antitumor
cell
contrast
tumor
aris
peripher
tissu
escap
immun
surveil
absenc
appropri
activ
cell
assess
whether
coronaviru
vectorbas
vaccin
prevent
growth
peripher
grow
tumor
appli
lcmvgp
recombin
lewi
lung
carcinoma
llc
cell
sc
prophylact
vaccin
mice
shown
figur
coronavirusbas
vector
abl
protect
anim
condit
howev
assess
efficaci
vaccin
therapeut
approach
ie
appli
vaccin
day
post
tumor
inocul
vector
achiev
almost
complet
block
tumor
growth
figur
taken
togeth
result
indic
differ
cytokin
improv
immunogen
coronaviru
vector
howev
matur
dc
vectorencod
cytokin
preferenti
activ
myeloid
cell
essenti
gener
therapeut
tumor
immun
recent
clinic
trial
shown
viral
vectorbas
vaccin
cancer
feasibl
safe
suitabl
achiev
protect
tumor
immun
exampl
random
placebocontrol
studi
patient
suffer
castrationresist
prostat
carcinoma
show
heterolog
primeboost
regimen
differ
poxviru
vector
deliv
prostatespecif
antigen
increas
median
surviv
month
notabl
approach
use
offtheshelf
vaccin
yield
efficaci
compar
person
cellular
vaccin
sipuleucel
increas
surviv
patient
suffer
incur
prostat
cancer
month
nonetheless
high
immunogen
viral
vector
result
induct
antivir
immun
make
heterolog
primeboost
scheme
necessari
guarante
repeat
exposur
target
antigen
henc
coronaviru
vector
base
human
dctarget
common
cold
virus
repres
potenti
asset
futur
clinic
trial
util
heterolog
primeboost
approach
importantli
vaccin
attenu
murin
coronaviru
vector
permit
usag
vector
even
homolog
primeboost
scheme
henc
lead
mainten
effector
cell
high
frequenc
sinc
human
coronavirus
caus
common
cold
frequent
reinfect
host
possibl
human
viral
vector
famili
may
util
well
homolog
primeboost
approach
abil
dc
induc
antigenspecif
tumor
immun
enhanc
immunolog
adjuv
tolllik
receptor
tlr
ligand
lead
optim
immun
activ
dc
stimul
directli
tlr
likewis
cytokin
stimul
myeloid
compart
granulocytemacrophag
colonystimul
factor
gmcsf
facilit
dc
matur
foster
surviv
previou
studi
reveal
import
dcspecif
gmcsf
deliveri
dc
matur
prolong
antigen
present
improv
dc
surviv
lead
sustain
cell
immun
viral
infect
tumor
found
second
myeloid
cellstimul
cytokin
effici
enhanc
immunogen
coronaviru
vector
notabl
vector
even
effect
gmcsf
vector
prevent
metastat
growth
melanoma
cell
moreov
vector
gmcsfencod
vector
elicit
broaden
epitop
repertoir
present
two
epitop
minigen
thu
iter
approach
coronaviru
vector
optim
use
singl
model
antigen
standard
readout
method
facilit
definit
cytokin
display
optim
adjuv
effect
vaccin
studi
also
evalu
adjuv
effect
cytokin
act
downstream
immun
activ
cascad
lymphocytestimul
cytokin
known
enhanc
prolifer
cell
foster
differenti
cell
control
format
cell
memori
howev
despit
share
two
three
receptor
unit
common
gamma
chain
cytokin
impact
differ
cell
differenti
import
earli
expans
cell
via
activationinduc
cell
death
limit
cell
overshoot
hand
essenti
surviv
highaffin
cell
memori
phase
ensur
therebi
mainten
protect
cell
memori
respons
import
note
highli
effici
adjuv
shown
enhanc
tumorspecif
cell
respons
data
confirm
improv
cell
activ
induct
prophylact
tumor
immun
also
incorpor
coronavirusbas
vaccin
deliv
cytokin
directli
dc
vivo
interest
note
neither
secret
system
act
local
act
transpres
reach
efficaci
dcstimul
highli
immunostimulatori
cytokin
support
exampl
control
parasit
infect
mice
human
moreov
effici
mobil
dc
precursor
exampl
human
metastat
colon
cancer
result
present
studi
suggest
high
vaccin
immunogen
achiev
direct
transduct
dc
via
coronaviru
vector
concomit
deliveri
potent
dc
matur
factor
clearli
analys
warrant
reveal
molecular
event
involv
adjuv
effect
system
addit
possibl
combin
differ
cytokin
deliv
coronaviru
vector
homolog
primeboost
regimen
eg
follow
vector
vice
versa
result
improv
coronaviru
vectorinduc
antitumor
immun
conclus
incorpor
cytokin
coronaviru
vector
substanti
improv
perform
sinc
vector
almost
exclus
target
dc
express
cytokin
facilit
dc
matur
foster
surviv
gmcsf
highli
effici
facilit
gener
mainten
antitumor
cell
therefor
coronavirusbas
vector
express
dcstimul
cytokin
develop
util
therapeut
cancer
vaccin
experi
perform
accord
feder
canton
guidelin
permiss
number
follow
review
approv
canton
veterinari
offic
st
gallen
switzerland
mice
obtain
charl
river
laboratori
sulzfeld
germani
tcr
transgen
mice
obtain
swiss
immunolog
mutant
mous
repositori
zurich
switzerland
mice
maintain
individu
ventil
cage
use
week
age
cell
kind
gift
g
sawicki
medic
univers
ohio
toledo
oh
lcmv
strain
obtain
r
zinkernagel
switzerland
titrat
mhv
vector
perform
describ
previous
gener
recombin
mhv
vector
base
revers
genet
system
establish
molecular
clone
product
recombin
coronaviru
particl
perform
previous
describ
bone
marrowderiv
dc
gener
cultur
erythrocytedeplet
bone
marrow
cell
day
presenc
gmcsf
contain
supernat
cell
line
kindli
provid
antoniu
rolink
univers
basel
basel
switzerland
describ
previous
dc
purifi
use
optiprep
densiti
gradient
centrifug
splenocyt
obtain
spleen
mice
follow
digest
collagenas
type
ii
min
resuspend
fc
isol
low
densiti
cell
splenocyt
resuspend
pb
supplement
fc
mm
edta
overlaid
optiprep
densiti
gradient
medium
sigmaaldrich
co
basel
switzerland
centrifug
min
low
densiti
cell
recov
interfac
resuspend
fc
cell
stain
differ
lineag
marker
analyz
egfp
express
facscanto
flow
cytomet
use
fac
diva
softwar
bd
bioscienc
antibodi
use
studi
purchas
bd
bioscienc
pharmingen
biolegend
ia
b
alexa
fluor
enumer
virusspecif
cell
ex
vivo
product
determin
tetram
stain
intracellular
cytokin
stain
respect
describ
previous
organ
remov
indic
time
point
follow
immun
mhvbase
vector
tetram
synthes
appli
stain
blood
spleen
sampl
previous
describ
intracellular
cytokin
stain
singl
cell
suspens
splenocyt
incub
h
roundbottom
plate
cultur
medium
contain
brefeldin
sigma
cell
stimul
phorbolmyristateacet
pma
ngml
ionomycin
ngml
purchas
sigma
buch
switzerland
posit
control
left
untreat
neg
control
analysi
peptidespecif
respons
cell
stimul
indic
peptid
cell
surfacestain
ebiosci
permeabil
cytofixcytoperm
bd
bioscienc
intracellularlystain
percentag
tet
cell
cell
produc
determin
use
facscanto
flow
cytomet
use
fac
diva
softwar
bd
bioscienc
kavynfatc
avynfatc
peptid
purchas
neosystem
strasbourg
franc
melanoma
cell
express
lcmv
epitop
parent
cell
kindli
provid
dr
h
pircher
univers
freiburg
germani
melanoma
cell
cultiv
life
technolog
gaithersburg
md
select
prophylact
vaccin
experi
mice
immun
mhvbase
vector
seven
day
iv
tumor
challeng
tumor
cell
protect
determin
number
metastas
foci
per
lung
day
twelv
post
tumor
inocul
therapeut
vaccin
mice
receiv
tumor
cell
iv
immun
ten
day
later
indic
vector
tumor
clearanc
determin
day
twenti
record
percentag
affect
lung
surfac
llc
cell
express
b
restrict
peptid
lcmv
glycoprotein
kindli
provid
dr
franca
ronches
univers
wellington
new
zealand
efficaci
prophylact
vaccin
assess
immun
mice
iv
pfu
coronaviru
vector
seven
day
sc
challeng
tumor
cell
left
flank
therapeut
vaccin
done
use
iv
applic
pfu
coronaviru
vector
mice
receiv
tumor
sc
left
flank
four
day
previous
indic
time
point
tumor
volum
record
x
wherebi
b
c
orthogon
diamet
statist
analys
perform
graphpad
prism
use
nonpair
two
tail
student
test
comparison
differ
group
done
use
one
way
anova
tukey
post
test
bonferroni
multipl
comparison
test
indic
statist
signific
defin
p
